MindMed

New Meme MindMed Executes 1:15 Reverse Stock Split
MindMed's First Patient Dosing Clinical Trial With LSD For Treatment Of Generalized Anxiety Disorder
MindMed Reports Promising Results For Non-Hallucinogenic Ibogaine Congener Substance
MindMed's First Patient Dosing Clinical Trial With LSD For Treatment Of Generalized Anxiety Disorder
MindMed Reports Promising Results For Non-Hallucinogenic Ibogaine Congener Substance
Can LSD Treat Anxiety? MindMed's New Topline Data Show Promise, Here's The Research
EXCLUSIVE: Lessons Learned At The Benzinga 2022 Psychedelics And Cannabis Capital Conferences

MindMed Recent News

Five Companies Developing Second Generation Psychedelics For Mental Health
MindMed Successfully Completes Phase 1 Trial Of 18-MC
This article was originally published on Microdose and appears here with permission.
MindMed Shares Update On Phase 2b Trials of LSD For Treating Generalized Anxiety Disorder
MindMed (NASDAQ: MNMD) (NEO: MMED), 
EXCLUSIVE: MindMed CEO Rob Barrow On Growth Aspirations, Development Pipeline
This past summer, Mind Medicine (MindMed) Inc (NASDAQ: MNMD), a medicine biotech in the psychedelics sector, announced the departure of co-founder and CEO J.R. Rahn.
How This Company Is Using Psychedelic Medicines and Therapies to Treat Addiction and Mental Illness
Courtesy of: MindMed The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Sponsored
EXCLUSIVE: Kevin O'Leary Unpacks Deal Flow, Investments, Perspectives On Disruptive Innovation
A lot has changed since Benzinga last spoke with Kevin O’Leary, businessman, author, "Shark Tank's" Mr. Wonderful.
Fintech Focus Roundup For June 13, 2021
Fintech Focus For June 11, 2021
EXCLUSIVE: Psychedelics Pioneer J.R. Rahn Unpacks Decision To Leave MindMed As CEO
Mind Medicine (MindMed) Inc (NASDAQ: MNMD) (NEO: MMED), a biotech company focused on the field of psychedelics, formally announced this week that J.R.
Fintech Focus For May 3, 2021
Quote To Start The Day: “In three words I can sum up everything I've learned about life: it goes on.”
Fintech Focus Roundup For May 2, 2021
MindMed's Nasdaq Listing Enables Institutions Diversified Access To A New Age Of Medicine
Mind Medicine (MindMed) Inc (NASDAQ: MNMD) (NEO: MMED), a leading medicine biotech company in psychedelics, this week began trading on the Nasdaq exchange.
Psyched: MindMed and Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Gets Back To Trading
Two of the most highly funded companies in the psychedelics space announced plans last week to list on the Nasdaq exchange.
Psyched: MindMed's 2020 Financials, Psychedelics ETF Rebalancing, Country's First Psychedelics Masters Degree
MindMed Posts 2020 Financials, New MDMA Dosing Study and 18-MC Patent Application MindMed (OTCQB:MMEDF) released its full-year 2020 financial results. 
Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week
Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap.
MindMed Reveals Results Of A Study On Personalized MDMA Dosing
Psychedelic medicine biotech company MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ) reported Monday the results of a study on MDMA dosing optimization utilizing perso
Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week
Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap.
Psyched: The Patents Dilemma, Compass 2020 Earnings, New Psilocybin Bill In NY
These days, the psychedelics finds itself in the midst of a public debate around the moral implications of patents and intellectual property for certain medicines and treatments.
Fintech Focus Roundup For February 20, 2020
Cannabis Movers & Shakers: TILT, MindMed, EnWave, Zelira
TILT Hires Two Compliance Experts
MindMed To Buy AI Medicine Company HealthMode For CA$42M
MindMed (NEO: MMED) (OTCQB: MMEDF) agreed to buy HealthMode, an artificial intelligence medicine company, in a CA$41.56 million (US$32.5 million) stock and cash deal.
Psyched: MindMed Enters Psychedelics 2.0, Mind Cure Raises $18M, Mydecine Raises $13M
Mind Cure Closes $18M Raise Mind Cure Health Inc. (CSE:MCUR) recently announced the closing of a CA$23 Million ($18.1 million) offering.
The Horizons Psychedelic Stock Index ETF, As Told By Its Fund Manager
On January 27, the Horizons Psychedelic Stock Index ETF (NEO:PSYK) became the first exchange traded fund to focus solely on the psychedelics industry. 

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved